Latest news with #EBV
Yahoo
12-06-2025
- Business
- Yahoo
Moderna explores outside financing for vaccine trials, shares dip
-- Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) shares fell 2.2% Thursday as the company confirmed it is seeking outside investment to support its late-stage vaccine programs. The move underscores the biotech firm's effort to align capital efficiency with strategic advancement across its product pipeline amid slowing COVID-19 revenue. 'We are very actively talking to potential partners right now,' CEO Stéphane Bancel said Wednesday at the Goldman Sachs Annual Global Healthcare Conference. He added that the discussions involved both pharmaceutical companies and financial partners, enabling the company to progress stalled late-stage candidates while controlling costs. A key focus for potential funding includes its latent virus vaccine programs, such as those targeting Epstein-Barr virus (EBV), herpes simplex virus (HSV), and varicella-zoster virus (VZV). 'We are working actively with [a] pharma company on the one hand and [a] financial partner on the other hand because we want those products to get to phase three,' Bancel said. Moderna has paused internal spending for those programs, opting instead to secure external capital and avoid further capital expenditure. 'We could launch EBV without adding $1 of CapEx. We could launch HSV without adding $1 of CapEx,' Bancel said, noting that Moderna's existing facilities have sufficient capacity to support production without the need for additional investment. The company's earlier collaboration with Blackstone (NYSE:BX) on financing a flu vaccine program stands as a precedent for these new deal structures. 'We would rather wait a few months to get the best partnership than being in a hurry and destroy value for shareholders by being in a hurry,' Bancel noted. While the company has over $8.5 billion in cash on hand, Bancel indicated this financing effort is about maximizing efficiency, not bridging funding gaps. 'We want to figure out who is the best partner in terms of capabilities and in terms of value,' he said, reiterating that securing the right structure is more important than speed. The funding push comes as Moderna aims to return to profitability by 2028 while ramping its oncology and respiratory portfolios. Shares finished the day down 2.2%, reflecting cautious sentiment amid uncertainty around vaccine uptake, trial timelines, and partnering outcomes. Related articles Moderna explores outside financing for vaccine trials, shares dip Israel considers military action against Iran, sources tell ABC News Micron boosts planned U.S. investment by $30 billion amid AI-driven demand Sign in to access your portfolio
Bloomberg
06-06-2025
- Health
- Bloomberg
The Silent Virus Behind Mono Is Now a Prime Suspect in Major Diseases
Jeff Cohen was 17 and living in Baltimore when mononucleosis knocked him off his feet. He thinks he got it from his high school girlfriend — now his wife — who once he got sick would ring the doorbell, drop off his homework and run away before he could get to the door. 'She was afraid I might give her something,' said Cohen, who was laid low for a week with a fever, sore throat and swollen glands. 'I'm certain it actually came from her.' That teenage case of mono, also known as glandular fever, would make a lasting impression. Five decades later, Cohen is now chief of the Laboratory of Infectious Diseases inside the National Institutes of Health, where he's leading efforts to create a vaccine for Epstein-Barr virus, or EBV, which causes mono.
Time of India
01-06-2025
- Health
- Time of India
Maycee Barber pulled from UFC main event, Erin Blanchfield slams her; here's what went wrong
Live Events What is the Epstein-Barr virus? Erin Blanchfield reacts (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel The sudden cancellation of the UFC Vegas 107 main event between Maycee Barber and Erin Blanchfield shocked fans. Just hours before the flyweight bout in Louisville, Kentucky, the UFC announced that Barber was 'medically unfit to compete.' It was later revealed that a severe flare-up of the Epstein-Barr virus (EBV) was the reason behind her 26, known as 'The Future,' had been on a five-fight win streak and was climbing the women's flyweight division ranks. The match against Blanchfield was highly anticipated, with many seeing it as a possible title eliminator. Barber had appeared fit during weigh-ins and promotional events throughout the week, which made her withdrawal all the more had arrived in Louisville, Kentucky, earlier in the week and appeared active during media day and weigh-ins. Her unexpected exit came after she had made weight and completed all promotional obligations, making the announcement all the more indicate that the medical issue arose shortly before the event, prompting the UFC's medical staff to pull her from the card for safety possible explanation is that Maycee Barber had to cut weight to compete in the flyweight division. This process can cause extreme dehydration and put severe stress on the body. Fighters often lose large amounts of water weight quickly, weakening the immune system and triggering underlying health Barber had been managing EBV-related health concerns for much of 2024. It is not known whether she has caught the disease Epstein-Barr virus is a member of the herpesvirus family and one of the most common viruses in humans. Most people are infected with it at some point in their lives. It's best known for causing infectious mononucleosis, commonly called 'mono', which results in fatigue, fever, sore throat, and swollen lymph some cases, EBV does not entirely disappear after the initial infection. It can remain dormant in the body and reactivate later, especially during stress, overtraining, or immune suppression. When reactivated, it can lead to severe fatigue, body aches, mental fog, and other symptoms that can persist for weeks or even months. This makes it especially challenging for athletes, whose performance depends on peak physical Blanchfield, who had been preparing for the biggest fight of her career, expressed her frustration after the cancellation. In a post-event interview, Blanchfield said, 'I feel like I've been robbed of a chance to prove myself. I was ready. I trained hard for this. This was supposed to be my statement fight.'Blanchfield didn't hold back when addressing Barber's withdrawal. 'It sucks. I don't know what happened. If it was really medical, I hope she's okay. But it's disappointing. We deserve answers, and fans deserve better,' she official word yet on when Barber might return to the octagon. She has not made a public statement about her health or a potential recovery timeline. The UFC has yet to announce whether the bout will be then, the women's flyweight division remains on pause.
Yahoo
29-05-2025
- Health
- Yahoo
Guardant Health, Inc. (GH) Expands Liquid Biopsy to Pinpoint Tumor Origins and Biomarkers
Guardant Health, Inc. (NASDAQ:GH) has introduced major upgrades to its Guardant360 Liquid biopsy test, significantly expanding its cancer biomarker detection and subtyping abilities. Utilizing the Guardant Infinity platform and AI-driven analysis, the test now offers comprehensive multiomic profiling from a simple blood draw. A patient viewing their medical diagnosis on a digital healthcare ecosystem. The enhanced test helps doctors quickly exclude actionable mutations in lung and colorectal cancers, identify cancer origins when unknown, and accurately classify breast and lung cancer subtypes through tumor methylation patterns. It also integrates pharmacogenomic data to guide safe drug use, detects viruses like HPV and EBV affecting treatment, assesses Homologous Recombination Deficiency (HRD) for targeted therapies, and uses HLA genotyping to inform therapy choices and clinical trial options. Guardant Health, Inc. (NASDAQ:GH)'s co-CEO Helmy Eltoukhy highlighted that this blood-based test provides vital tumor insights without needing tissue samples, delivering results within seven days and enabling faster, smarter cancer treatment decisions. While we acknowledge the potential of GH to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GH and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
Business Wire
17-05-2025
- Business
- Business Wire
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective following the completion the Company's previously announced $16 million offering that was announced on May 15, 2025. The offering closed on May 16, 2025. Mr. Huang has over 37 years of biotech experience and is the Founder and Managing Partner of Panacea Venture. Prior to Panacea Venture, Mr. Huang was a Managing Partner at Kleiner Perkins (KPCB) China where he focused on the firm's life sciences practice, and a managing partner at Vivo Ventures where he led numerous investments in China. He was also the president of Anesiva, Inc., a biopharmaceutical company focused on pain-management treatments. Earlier in his career, he held senior roles in business development, sales, marketing, and research and development with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Myers Squibb and ALZA Corp. (acquired by Johnson & Johnson). Additionally, Mr. Huang serves as a member of the board of directors of Kindstar Globalgene Technology, Inc., Connect Biopharma Holdings Limited, Lee's Pharmaceutical Holdings Limited and several private companies. He received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley. Nachi Subramanian has served as a Managing Director at the Redmile Group since December 2021. He previously spent fourteen years at J.P. Morgan, where he held senior roles across the Private Markets and Global Cash Equities businesses. Nachi began his career in Institutional Equities at Bear Stearns. He holds a B.A. in Political Science and Economics from the University of California, Irvine. About Atara Biotherapeutics, Inc. Atara is a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr Virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases. Atara is headquartered in Southern California.
